Cargando…
COVID-19 vaccine capacity: Challenges and mitigation – The DCVMN perspective
Vaccine manufacturers from developing countries have a proven track record of developing, producing, and supplying high-quality vaccines globally. However, due to the complexity of vaccine manufacturing, numerous stakeholder organizations support manufacturers across a variety of functions. To optim...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275514/ https://www.ncbi.nlm.nih.gov/pubmed/34325932 http://dx.doi.org/10.1016/j.vaccine.2021.07.007 |
_version_ | 1783721731334078464 |
---|---|
author | Hayman, Benoit Suri, Rajinder Prasad, Sai D. |
author_facet | Hayman, Benoit Suri, Rajinder Prasad, Sai D. |
author_sort | Hayman, Benoit |
collection | PubMed |
description | Vaccine manufacturers from developing countries have a proven track record of developing, producing, and supplying high-quality vaccines globally. However, due to the complexity of vaccine manufacturing, numerous stakeholder organizations support manufacturers across a variety of functions. To optimize the support from stakeholders it is instrumental to first understand which manufacturing processes these manufacturers require support for and what support functions are most beneficial. To this end, the Developing Countries Vaccine Manufacturers Network designed a comprehensive survey to assess the specific needs of the Network’s member organizations. We found that almost all sampled manufacturers are interested in obtaining funding or technology transfers for COVID-19 vaccines. Furthermore, results indicated that manufacturers have a strong appetite for modern technology platforms, particularly RNA technologies. Scale-up, phase III clinical trials, and formulation were also key processes for which manufacturers require support. |
format | Online Article Text |
id | pubmed-8275514 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82755142021-07-14 COVID-19 vaccine capacity: Challenges and mitigation – The DCVMN perspective Hayman, Benoit Suri, Rajinder Prasad, Sai D. Vaccine Short Communication Vaccine manufacturers from developing countries have a proven track record of developing, producing, and supplying high-quality vaccines globally. However, due to the complexity of vaccine manufacturing, numerous stakeholder organizations support manufacturers across a variety of functions. To optimize the support from stakeholders it is instrumental to first understand which manufacturing processes these manufacturers require support for and what support functions are most beneficial. To this end, the Developing Countries Vaccine Manufacturers Network designed a comprehensive survey to assess the specific needs of the Network’s member organizations. We found that almost all sampled manufacturers are interested in obtaining funding or technology transfers for COVID-19 vaccines. Furthermore, results indicated that manufacturers have a strong appetite for modern technology platforms, particularly RNA technologies. Scale-up, phase III clinical trials, and formulation were also key processes for which manufacturers require support. Elsevier Ltd. 2021-08-16 2021-07-13 /pmc/articles/PMC8275514/ /pubmed/34325932 http://dx.doi.org/10.1016/j.vaccine.2021.07.007 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Short Communication Hayman, Benoit Suri, Rajinder Prasad, Sai D. COVID-19 vaccine capacity: Challenges and mitigation – The DCVMN perspective |
title | COVID-19 vaccine capacity: Challenges and mitigation – The DCVMN perspective |
title_full | COVID-19 vaccine capacity: Challenges and mitigation – The DCVMN perspective |
title_fullStr | COVID-19 vaccine capacity: Challenges and mitigation – The DCVMN perspective |
title_full_unstemmed | COVID-19 vaccine capacity: Challenges and mitigation – The DCVMN perspective |
title_short | COVID-19 vaccine capacity: Challenges and mitigation – The DCVMN perspective |
title_sort | covid-19 vaccine capacity: challenges and mitigation – the dcvmn perspective |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275514/ https://www.ncbi.nlm.nih.gov/pubmed/34325932 http://dx.doi.org/10.1016/j.vaccine.2021.07.007 |
work_keys_str_mv | AT haymanbenoit covid19vaccinecapacitychallengesandmitigationthedcvmnperspective AT surirajinder covid19vaccinecapacitychallengesandmitigationthedcvmnperspective AT prasadsaid covid19vaccinecapacitychallengesandmitigationthedcvmnperspective |